Amgen Seeks High Court Review Of Investor Class Cert.
By Amanda Bransford · March 7, 2012, 5:19 PM EST
Amgen Inc. asked the U.S. Supreme Court last week to review the Ninth Circuit's refusal to decertify a class of shareholders who allege Amgen misled investors about two top-selling anemia drugs,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login